VYLOY (zolbetuximab) in combination with chemotherapy is NOW AVAILABLE and approved for first-line treatment of eligible* adult patients with gastric or gastroesophageal junction adenocarcinoma in India
Partially corroborated51– VYLOY is the first and only CLDN18.2-targeted treatment approved in the India for adult patients with HER2 negative gastric and gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive – – Central Drugs Standard Control Organization approval was based on the global Phas...
First seen · latest update · India · other
Developing: this story surfaced recently from a single outlet. It appears early by design — expect the reporting-confidence score to move as more outlets report (or don’t).
- Indian mainstream 0
- Indian independent 1
- International 0
- Official 0
See a mistake? Wrong summary · Wrongly grouped · Missing source · Wrong category/region · Dispute outlet rating — each opens a pre-filled report on GitHub.